Clinical trial
A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary Fibrosis
NCT07933133 is registered in ClinicalTrials.gov with CSPC-NBP Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary Fibrosis
- Lead sponsor
- CSPC-NBP Pharmaceutical Co., Ltd.
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- February 1, 2030
- Enrollment
- 300 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 7 arms.
-
Group A1
Group SYH9061 4 mg
-
Group A2
Group Placebo
-
Group B1
Group SYH9061 6 mg
-
Group B2
Group Placebo
-
Group C1
Group SYH9061 4 mg
+2 more arms
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change in FVC from baseline (mL)
FVC is one of the pulmonary function indicators; FVC values in patients with IPF tend to decrease.
Lead sponsor's other trials
CSPC-NBP Pharmaceutical Co., Ltd., most recent start first.
Similar trials
Same condition (Idiopathic Pulmonary Fibrosis) and phase, most recent start first.
+132 more trials See the condition page